Corcept Therapeutics said on Monday its experimental drug in combination with chemotherapy helped delay progression of a type ...
A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...
Northwestern Medicine scientists have uncovered new details about the genetic structure of ovarian cancer stem cells, ...
Acrivon Therapeutics is halting work on developing its lead drug for ovarian and bladder cancers, instead focusing the Eli ...
Nemvaleukin alfa with pembrolizumab missed the overall survival primary end point in ARTISTRY-7 for platinum-resistant ...
Oregon State University scientists have developed a highly efficient, uniquely shaped magnetic nanoparticle that could enable ...
Evaluation of nemvaleukin for platinum-resistant ovarian cancer will be terminated based on OS data from an interim analysis ...
A comparison of patients with and without BRCA gene mutations receiving prophylactic risk-reduction surgery suggest ...
A real-world study reveals the need for increased homologous repair deficiency and BRCA1/2 testing in patients with ovarian ...
“How I Knew I Had Ovarian Cancer”: A Patient’s Story Reveals an Unexpected Benefit of Daily Exercise
A woman's story of literal strength shows how ovarian cancer can be missed—and the lighthearted recovery milestone every care ...
REDWOOD CITY, CA, USA I March 31, 2025 I Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development ...
A significant study detailing OncoSeek®'s efficacy was published in eClinicalMedicine, a clinical journal of The Lancet, titled A panel o ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback